Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
06 02 2019
Historique:
received: 25 06 2018
revised: 17 09 2018
accepted: 15 01 2019
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 23 2 2020
Statut: ppublish

Résumé

Metabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in disease progression is unclear. We investigated the role of lipid metabolism in prostate cancer using tissue from patients with prostate cancer and patient-derived xenograft mouse models. We showed that fatty acid uptake was increased in human prostate cancer and that these fatty acids were directed toward biomass production. These changes were mediated, at least partly, by the fatty acid transporter CD36, which was associated with aggressive disease. Deleting

Identifiants

pubmed: 30728288
pii: 11/478/eaau5758
doi: 10.1126/scitranslmed.aau5758
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
CD36 Antigens 0
Fatty Acids 0
RNA, Small Interfering 0
PTEN Phosphohydrolase EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Matthew J Watt (MJ)

Department of Physiology, University of Melbourne, Melbourne, VIC 3010, Australia. matt.watt@unimelb.edu.au renea.taylor@monash.edu.
Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Ashlee K Clark (AK)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.

Luke A Selth (LA)

Dame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men's Health, Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia.

Vanessa R Haynes (VR)

Department of Physiology, University of Melbourne, Melbourne, VIC 3010, Australia.
Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Natalie Lister (N)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.

Richard Rebello (R)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.
Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4GJ, UK.

Laura H Porter (LH)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.

Birunthi Niranjan (B)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.

Sarah T Whitby (ST)

Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Jennifer Lo (J)

Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Cheng Huang (C)

Monash Biomedical Proteomics Facility and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.

Ralf B Schittenhelm (RB)

Monash Biomedical Proteomics Facility and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.

Kimberley E Anderson (KE)

Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology, University of California, Berkley, Berkeley, CA, USA.

Luc Furic (L)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.
Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.

Poornima R Wijayaratne (PR)

Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Maria Matzaris (M)

Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Magdalene K Montgomery (MK)

Department of Physiology, University of Melbourne, Melbourne, VIC 3010, Australia.
Monash Biomedicine Discovery Institute, Metabolic Disease and Obesity, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.

Melissa Papargiris (M)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.

Sam Norden (S)

TissuPath, Mount Waverley, VIC 3149, Australia.

Maria Febbraio (M)

Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2R7, Canada.

Gail P Risbridger (GP)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.
Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.

Mark Frydenberg (M)

Department of Surgery, Faculty of Medicine, Monash University, Clayton, VIC 3800, Australia.

Daniel K Nomura (DK)

Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology, University of California, Berkley, Berkeley, CA, USA.

Renea A Taylor (RA)

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Physiology, Monash University, Clayton, VIC 3800, Australia. matt.watt@unimelb.edu.au renea.taylor@monash.edu.
Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC 3800, Australia.
Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH